COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.

ABSTRACT:

Introduction

Chronic myeloid leukemia (CML) is a severe hematological malignancy characterized by BCR-ABL fusion gene. The advent of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL has improved the landscape of CML treatment dramatically. The occurrence of coronavirus disease 2019 (COVID-19) has challenged many cancers. However, its effect on TKI therapy of CML remains unknown.

Methods

In this study, we collected peripheral blood from chronic phase CML patients treated with TKIs at low-level BCR-ABL P210 during COVID-19 pandemic, and determined the alterations of BCR-ABL P210 by applying the well-established BCR-ABL P210 detection system.

Results

Our results showed that the level of BCR-ABL P210 of CML patients was significantly elevated shortly after contracting

SUBMITTER: He N 

PROVIDER: S-EPMC11615079 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature